Pallone Leads NJ Congressional Delegation Letter Supporting Rutgers’ Application to be a National Cancer Institute
Washington, DC - Congressman Frank Pallone, Jr. (NJ-06) led a bipartisan letter with members of the New Jersey’s Congressional delegation expressing their support for Rutgers Cancer Institute of New Jersey's application for recognition as a National Cancer Institute (NCI)- Designated Comprehensive Cancer Center. Originally recognized as an NCI-Designated cancer center in 1997, the Rutgers Cancer Institute is one of only 49 such centers nationwide, and the only one in the entire state of New Jersey.
Beyond its primary role of improving healthcare, the institute has also served a strong economic role in the state by returning $13 to NJ for every dollar of federal funding. Rep. Pallone hopes that the designation, which is thoroughly deserved, will help boost the role that the Rutgers Cancer Institute plays in advancing research and developing innovative treatments and screening methods.
U.S. Senators Robert Menendez and Cory Booker, and Representatives Frank LoBiondo (NJ-02), Rodney Frelinghuysen (NJ-11), Leonard Lance (NJ-07), Donald Norcross (NJ-01), Bill Pascrell (NJ-09) Donald M. Payne, Jr. (NJ-10), Albio Sires (NJ 0-8), and Bonnie Watson Coleman (NJ-12) all signed the letter.
Dr. Steven K. Libutti, MD, FACS
Director, Rutgers Cancer Institute of New Jersey
195 Little Albany Street
New Brunswick, NJ 08903-2681
Dear Dr. Libutti:
As members of New Jersey’s Congressional delegation, we write in support of the Rutgers Cancer Institute of New Jersey’s application for recognition as a National Cancer Institute (NCI)-Designated Comprehensive Cancer Center. This certification is of critical importance to the health and well-being of the people of New Jersey.
Originally recognized as an NCI-Designated cancer center in 1997, the Rutgers Cancer Institute is one of only 49 such centers nationwide, and the only one in the entire state of New Jersey. The Rutgers Cancer Institute has played a significant role in American cancer research and clinical care. Its cancer researchers and clinicians apply the latest technologies, therapies, and approaches to improve precision medicine, immunotherapy, epidemiology, chemical carcinogenesis, tumor virology, drug development and resistance, and cancer genomics, among other advances.
The Rutgers Cancer Institute serves a unique role in New Jersey, and is an economic engine for the state. According to a 2015 independent economic impact report, for every dollar of federal funding that was granted to the Rutgers Cancer Institute, $13 were returned to the state. Among its unique contributions, cancer researchers at Rutgers Cancer Institute are able to study New Jersey’s diverse population to better understand rare cancers and those more common in minority populations, where cancer research and breakthroughs have been lagging. As a member of the Big Ten Cancer Research Consortium, the institute conducts highly translational oncology trials that leverage the scientific and clinical expertise of Big Ten Universities.
The work taking place at Rutgers Cancer Institute of New Jersey is advancing cancer clinical care, research, and awareness across the state and country. We are proud to support Rutgers’ application for certification as an NCI-designated Comprehensive Cancer Center. We look forward to learning of the outcome of this application.